Investors & Media

Corporate Profile

Millendo Therapeutics is a biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases. We create distinct and transformative treatments for endocrine diseases where there is a significant unmet medical need. We are currently advancing a pipeline that includes the following product candidates:

  • Nevanimibe (ATR-101) for the treatment of classic congenital adrenal hyperplasia
  • MLE-301 for the treatment of vasomotor symptoms (VMS) associated with menopause

Corporate Presentation

More information is coming soon.

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.